Harris Kaplan, Managing Partner, has extensive experience on both the client and consulting sides of the life sciences industry. He has worked on the introduction of more than 100 new products including Lipitor, Crestor, Nexium, Rituxan, and Herceptin. More recently, Harris worked on the introduction of Incivek, Kalydeco, and worked as the CCO for Auspex prior to its acquisition by Teva.
Harris is an expert at product positioning and segmentation, identifying unique opportunities for new and on the market products. His expertise comes from a long history in interviewing thousands of physicians, payers, and patients across many therapeutic categories. He has been a frequent speaker on creating a compelling value proposition and was elected as 100 most inspirational people by Pharma Voice in 2011.
Harris, who serves as the President and Chief Executive Officer of Healogix, co-founded Migliara-Kaplan Associates which was acquired by Interpublic Group and Cozint Interactive, acquired by GFK. He is an advisor to several venture capital funds, and sits on the Board of Directors of the Kernan Orthopedic Hospital.
Joe Plevelich, Managing Director, has over 30 years of comprehensive senior management, P&L, sales/marketing and business development experience both on the client and consulting sides of the life science industry. He has built successful sales teams, corporate partnerships and distributor licensee operations worldwide.
Joe’s past experience includes 20 years with the DuPont Company in various job assignments of increasing responsibility, which included leading DuPont International Pharmaceutical and Radio Pharmaceutical businesses. Additionally, Joe held Worldwide positions in Glucose Monitoring Systems both at Becton Dickinson and Boehringer Mannheim, was Assistant Vice President of New Products Marketing/Business Development at Wyeth, was Vice President of worldwide sales and marketing for INO Therapeutics and was Vice President of Sales Force Effectiveness and Managed Care Consulting for IMS Health.
Joe has a Bachelor’s degree from West Virginia University and an MBA from St. Joseph’s University.
Eric Nelson, Managing Director, has 25 years experience at pharmaceutical, biotechnology, and CRO companies. In business development compound licensing, and strategic research planning, he has conducted due diligence assessments of hundreds of therapeutic programs.
His core expertise is understanding the drug scientific and clinical aspects and working cross-functionally to support portfolio development. He helped the NIH launch its successful rare diseases program, and was the NIH’s industry liaison for the rare disease, heart-lung and blood, and neurology translational research areas. In compound licensing, he has closed on 50 compound licensing partnerships in deals worth over $1B.
His corporate positions were at Pfizer, Becton Dickinson, Elan, Advinus, and Cowen & Co.
He has helped build 4 biotech companies from start-up through successful IPO or acquisition exits.
Eric has a Ph.D. from Johns Hopkins School of Medicine and conducted post-doctoral research at Harvard University in oncology drug discovery research.
Lori Thompson, Managing Director, has over 30 years of experience in senior leadership roles in the medtech industry, with significant experience in marketing/sales, M&A, licensing and partnerships, and global P&L management.
Her medtech experience encompasses devices and software products targeting the hospital, subacute, physician office, home, and telemedicine space. Most recently she held a CEO position at a pre-commercial start up in imaging technologies.
Lori’s past experience includes 16 years with Covidien and its antecedent companies, with increasing levels of responsibility for global upstream and downstream marketing, global strategy, and business development and portfolio management. After leaving Covidien Lori was VP of global marketing for Cardinal Health’s respiratory business, and came to CareFusion with their spin-out from Cardinal Health as VP of global marketing for the infusion business. Lori’s strengths lie in developing compelling global strategies and positioning, paired with targeted execution plans to achieve those strategies.
Lori holds a bachelor’s degree from Duke University.